Table of Content

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Why do companies partner at discovery stage?

2.1. Introduction
2.2. The role of discovery stage partnering
2.2.1. In-licensing at discovery stage
2.2.2. Out-licensing at discovery stage
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into discovery stage partnering deals
2.4.1. Licensors reasons for entering discovery stage deals
2.4.2. Licensees reasons for entering discovery stage deals
2.5. The future of discovery stage partnering deals

Chapter 3 – Discovery stage deal strategies and structure

3.1. Introduction
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical/biotech
3.2.1.1. Discovery and preclinical stage partnering case studies
3.2.1.1.a. Case study: LEO Pharma - 4SC
3.2.1.1.b. Case study: Heptares Therapeutics - Cubist
3.2.1.1.c. Case study: Incyte – Agenus Bio
3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec
3.2.2. Partnering later in pharmaceutical/biotech
3.2.2.1. Clinical stage partnering case studies
3.2.2.1.a. Case study: Servier – GeNeuro
3.2.2.1.b. Case study: Teva – Xenon Pharmaceuticals
3.2.2.1.c. Case study: AstraZeneca - Ardelyx
3.2.2.1.d. Case study: Baxter – Onconova Therapeutics
3.3. Early and later stage partnering – a risk/cost comparison
3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure licensing agreements
3.6.1.a. Case study : Pfizer – Spark Therapeutics
3.6.1.b. Case study : Contrafect – Trellis Bioscience
3.7. Multicomponent discovery stage partnering agreements
3.7.1.a. Example multicomponent early stage clauses
3.7.1.a. Case study: Tracon – Boehringer Ingelheim – Macrogenics
3.7.1.b. Case study: Fibrocell Science – Intrexon

Chapter 4 – Discovery stage partnering payment strategies

4.1. Introduction
4.2. Discovery stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
4.3.2.1. Conditionality of upfront payments
4.3.3. Loans
4.3.4. Convertible loans
4.3.5. Equity
4.3.6. R&D funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
4.3.9.1. Issues affecting royalty rates
4.3.9.2. Royalties on combination products
4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech
4.3.9.3. Guaranteed minimum/maximum annual payments
4.3.9.4. Royalty stacking
4.3.9.5. Royalties and supply/purchase contracts
4.3.10. Quids
4.3.11. Option payments

Chapter 5 – Trends in discovery stage deal making

5.1. Introduction
5.2. Discovery stage partnering over the years
5.2.1. Attributes of discovery deals
5.3. Discovery stage partnering by deal type
5.4. Discovery stage partnering by disease type
5.5. Partnering by discovery stage technology type
5.6. Discovery stage partnering by most active company since 2014

Chapter 6 – Payment terms for discovery stage partnering

6.1. Introduction
6.2. Guidelines for discovery stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Discovery stage payment terms – deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Discovery stage headline values
6.4.2. Discovery stage deal upfront payments
6.4.3. Discovery stage deal milestone payments
6.4.4. Discovery stage royalty rates

Chapter 7 – Leading discovery stage deals

7.1. Introduction
7.2. Top discovery stage deals by value

Chapter 8 – Top 25 most active discovery stage dealmakers

8.1. Introduction
8.2. Top 25 most active discovery stage dealmakers

Chapter 9 – Discovery stage partnering contracts directory

9.1. Introduction
9.2. Discovery stage deals with contracts 2014 to 2020

Chapter 10 – Discovery stage deal making by development stage

10.1. Introduction
10.2. Deals by discovery stage

Appendices

Appendix 1 – Discovery stage dealmaking by companies A-Z
Appendix 2 – Discovery stage dealmaking by industry sector
Appendix 3 – Discovery stage dealmaking by stage of development
Appendix 4 – Discovery stage dealmaking by therapy area
Appendix 5 – Discovery stage dealmaking by technology type

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

Table of figures

Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
Figure 2: Components of the pure licensing deal structure
Figure 3: Payment options for discovery stage partnering deals
Figure 4: Issues affecting royalty rates
Figure 5: Discovery stage partnering frequency 2014- 2020
Figure 6: Discovery stage partnering by deal type since 2014
Figure 7: Discovery stage partnering by disease type since 2014
Figure 8: Discovery stage partnering by technology type since 2014
Figure 9: Top 25 most active discovery stage dealmakers, 2014 to 2020
Figure 10: Review of median upfront payments for discovery stage deals
Figure 11: Review of median milestone payments for discovery stage deals
Figure 12: Review of median royalty payments for discovery stage deals
Figure 13: Discovery stage deals with a headline value
Figure 14: Discovery stage deals with an upfront value
Figure 15: Discovery stage deals with a milestone value
Figure 16: Discovery stage deals with a royalty rate value
Figure 17: Top discovery stage deals that exceeds $1 billion in deal value since 2014
Figure 18: Most active discovery stage dealmakers 2014 to 2020